OBJECTIVE: To compare the binding to cultured endothelial cells of mononuclear cells isolated from healthy volunteers and patients with NIDDM. RESEARCH DESIGN AND METHODS: Mononuclear cells were isolated from healthy volunteers (n = 11) and patients with NIDDM (n = 14) and incubated with ECV 304 cells, a human umbilical endothelial cell-derived transformed cell line. Following a period of incubation, the adherence of mononuclear cells to endothelial cells was determined. RESULTS: Adherence of mononuclear cells from patients with NIDDM was significantly greater (P < 0.05) than that of cells isolated from the healthy volunteers, and this difference persisted when adjusted for age, sex, and degree of obesity. Mononuclear cell binding to ECV 304 cells correlated significantly with fasting plasma glucose (r = 0.52, P < 0.01), insulin (r = 0.51, P < 0.01), triglyceride (r = 0.54, P < 0.01), and VLDL (r = 0.54, P < 0.01) and HDL cholesterol (r = -0.45, P < 0.05) levels, but not with either total or LDL cholesterol levels or blood pressure. CONCLUSIONS: Since the adherence of mononuclear cells to the endothelium represents the earliest step in atherogenesis, the observation that mononuclear cells from patients with NIDDM bind more avidly to cultured endothelial cells may help explain why accelerated atherosclerosis occurs in patients with NIDDM. The metabolic abnormality, or abnormalities, present in patients with NIDDM that is responsible for the enhanced adhesiveness of mononuclear cells requires further examination.
OBJECTIVE: To compare the binding to cultured endothelial cells of mononuclear cells isolated from healthy volunteers and patients with NIDDM. RESEARCH DESIGN AND METHODS: Mononuclear cells were isolated from healthy volunteers (n = 11) and patients with NIDDM (n = 14) and incubated with ECV 304 cells, a human umbilical endothelial cell-derived transformed cell line. Following a period of incubation, the adherence of mononuclear cells to endothelial cells was determined. RESULTS: Adherence of mononuclear cells from patients with NIDDM was significantly greater (P < 0.05) than that of cells isolated from the healthy volunteers, and this difference persisted when adjusted for age, sex, and degree of obesity. Mononuclear cell binding to ECV 304 cells correlated significantly with fasting plasma glucose (r = 0.52, P < 0.01), insulin (r = 0.51, P < 0.01), triglyceride (r = 0.54, P < 0.01), and VLDL (r = 0.54, P < 0.01) and HDL cholesterol (r = -0.45, P < 0.05) levels, but not with either total or LDL cholesterol levels or blood pressure. CONCLUSIONS: Since the adherence of mononuclear cells to the endothelium represents the earliest step in atherogenesis, the observation that mononuclear cells from patients with NIDDM bind more avidly to cultured endothelial cells may help explain why accelerated atherosclerosis occurs in patients with NIDDM. The metabolic abnormality, or abnormalities, present in patients with NIDDM that is responsible for the enhanced adhesiveness of mononuclear cells requires further examination.
Authors: Thomas Kunt; Thomas Forst; Christof Kazda; Oliver Harzer; Martin Engelbach; Mirjam Löbig; Jürgen Beyer; Andreas Pfützner Journal: J Diabetes Sci Technol Date: 2007-11
Authors: Kyoungmin Park; Qian Li; Net Daş Evcimen; Christian Rask-Madsen; Yasutaka Maeda; Ernesto Maddaloni; Hisashi Yokomizo; Takanori Shinjo; Ronald St-Louis; Jialin Fu; Daniel Gordin; Mogher Khamaisi; David Pober; Hillary Keenan; George L King Journal: Arterioscler Thromb Vasc Biol Date: 2017-11-21 Impact factor: 8.311
Authors: Alice Liu; Tracey McLaughlin; Teresa Liu; Arthur Sherman; Gail Yee; Fahim Abbasi; Cindy Lamendola; John Morton; Samuel W Cushman; Gerald M Reaven; Philip S Tsao Journal: Obes Surg Date: 2009-08-27 Impact factor: 4.129
Authors: T McLaughlin; A Deng; G Yee; C Lamendola; G Reaven; P S Tsao; S W Cushman; A Sherman Journal: Diabetologia Date: 2009-10-09 Impact factor: 10.122
Authors: T McLaughlin; A Sherman; P Tsao; O Gonzalez; G Yee; C Lamendola; G M Reaven; S W Cushman Journal: Diabetologia Date: 2007-06-05 Impact factor: 10.122